Injectables
Galderma Wins FDA Approval for Restylane Contour — Temple Hollowing Now Indicated
Galderma expands its crosslinked HA portfolio into midface contouring, competing directly with volumizers.
AI Inside MedSpa Intelligence · Jun 26, 2026
Galderma has received FDA approval for Restylane Contour for the correction of temple hollowing and age-related volume loss in the temple region. The indication represents a strategic expansion of the Restylane family into a specific anatomical zone where volumization is increasingly demanded.
Temple hollowing is a hallmark of facial aging and a common patient concern, particularly in the 45+ demographic. Restylane Contour's crosslinked HA structure positions it as a durable volumizer in a zone that demands both lift and natural contour. The approval directly competes with AbbVie's Juvéderm Voluma and Galderma's own Restylane Lyft, but the temple-specific indication allows for targeted marketing and potentially distinct reimbursement coding.
FDA-cleared for temple hollowing—a high-demand zone with limited prior options.
For practices, this approval signals Galderma's continued investment in anatomically specific indications—a strategy that supports premium pricing and differentiation from generic volumization claims. Expect promotional activity and potential Aspire loyalty program incentives.
Source: original report ↗
Frequently asked questions
What is Restylane Contour FDA approved for?
Restylane Contour is FDA approved for the correction of temple hollowing and age-related volume loss in the temple region. This represents Galderma's first temple-specific indication for its crosslinked HA portfolio.
How does Restylane Contour compare to Juvéderm Voluma for temple treatment?
Both are volumizers, but Restylane Contour now has a specific FDA indication for temple hollowing, while Juvéderm Voluma is indicated for cheek augmentation. The temple-specific approval allows Restylane Contour distinct reimbursement coding and targeted marketing positioning.
What age group is temple hollowing most common in?
Temple hollowing is a hallmark of facial aging particularly prevalent in the 45+ demographic. It's a common patient concern that drives demand for volumization in the midface region.
Why is the temple-specific indication important for medspa practices?
The anatomically specific indication supports premium pricing and differentiation from generic volumization claims. It also enables distinct reimbursement coding and allows practices to market Restylane Contour as purposefully designed for temple contouring rather than off-label use.
Does Galderma offer loyalty incentives for Restylane Contour?
Yes, Galderma's Aspire loyalty program is expected to provide promotional activity and potential incentives for practices using Restylane Contour, supporting adoption of the newly approved indication.
Free weekly brief Get the free weekly brief.
The week's most important moves in medical aesthetics — distilled to a two-minute read, free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief every morning. The owners who read it never get blindsided.
Get the edge · $20/mo Join the owners who run ahead of the industry. Cancel anytime, one click.
